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Objectives: 1.) Assess utility of biomarkers as a surrogate endpoint and a reflection of total body burden of 
Gaucher cells by examining correlations between biomarkers and liver volume and characterizing 
biomarker response to enzyme replacement therapy (ERT), and 2.) to gain insight into pathophysiologic 
pathways of GD. 
Study Design: This is an observational study 
Subjects and Methods: 114 patients with both pretreatment and post-treatment data were identified.  
These patients were further subdivided into intact spleen and asplenic patients.  Differences in means 
among the subgroups of patients were determined, then regression analyses were run to investigate 
correlations between biomarkers and liver volume.  Multiple serial measurements of liver volume, spleen 
volume, and chitotriosidase while undergoing ERT were graphed in a subgroup of 5 patients. 
Results: ACE, ferritin, transferrin saturation percentage, platelet count, and white blood cell count are all 
significantly increased in asplenic patients compared intact spleen patients.  Correlations with liver volume 
and biomarkers were weak, but some were significant: In intact spleen patients, liver volume was positively 
correlated with chitotriosidase and ACE and negatively correlated with HDL, LDL, hemoglobin, and white 
blood cell count.  In asplenic patients, liver volume was positively correlated with ACE and platelets.  
Chitotriosidase vs. liver volume and spleen volume responses to ERT showed a sigmoid curve.  
Conclusion: This study shows that certain biomarker levels are increased in asplenic GD patients, 
suggesting that the spleen normally traps these substances in circulation.  In addition, there were weak and 
inconsistent correlations between biomarkers and liver volume.  These results in addition to the sigmoid 
shape of the relationship between spleen volume and liver volume with chitotriosidase levels indicate that 
chitotriosidase and perhaps other biomarkers are excreted from other organs as well.  
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